Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

693
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
693
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

3.2K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.2K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

296
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
296

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ambient PM<sub>2</sub>.<sub>5</sub> exposure and increased dengue case fatality: a global multi-country analysis.

Environmental pollution (Barking, Essex : 1987)·2026
Same author

Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure.

Hepatology international·2025
Same author

NS1 Rapid Card Test for Dengue Detection: Insights from the 2023 Outbreak in Bangladesh.

International journal of general medicine·2025
Same author

Global Burden of Major Chronic Liver Diseases in 2021.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021.

JHEP reports : innovation in hepatology·2025
Same author

Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia.

Hepatology international·2025

Related Experiment Video

Updated: Mar 13, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Immune therapy for hepatitis B.

Sheikh Mohammad Fazle Akbar1, Mamun Al-Mahtab2, Md Sakilur Islam Khan3

  • 1Department of Medical Sciences, Toshiba General Hospital, Tokyo, Japan.

Annals of Translational Medicine
|October 21, 2016
PubMed
Summary
This summary is machine-generated.

Current antiviral treatments for chronic hepatitis B (CHB) have limitations. Immune therapy offers a promising alternative for CHB patients by restoring immune function.

Keywords:
Chronic hepatitis B (CHB)HBV antigen-specificimmune therapypathogenic immunitypolyclonal immune modulatorstherapeutic immunity

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Related Experiment Videos

Last Updated: Mar 13, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Area of Science:

  • Hepatology
  • Immunology
  • Virology

Background:

  • Antiviral therapies for chronic hepatitis B (CHB) often fail to achieve sustained responses or prevent complications.
  • Long-term antiviral use carries risks of drug resistance and toxicity, and high costs limit accessibility in resource-constrained regions.
  • CHB is associated with impaired immune responses, suggesting immunotherapy as a potential alternative.

Approach:

  • This review discusses the properties and features of immune therapy for CHB.
  • It examines various immunomodulatory agents and clinical trial outcomes.
  • The focus is on developing guidelines for effective immune therapeutic regimens.

Key Points:

  • Immune responses are often compromised in CHB patients.
  • Restoring or inducing appropriate immune responses may be therapeutically beneficial.
  • The design and properties of immune modulators are critical for successful CHB treatment.

Conclusions:

  • There is a significant need for novel therapeutic strategies beyond current antiviral drugs for CHB.
  • Immunotherapy presents a viable alternative by targeting the immune system's role in CHB.
  • Further research into optimizing immune therapy regimens is essential for improved patient outcomes.